Tezepelumab Granted Priority Review By U.S. FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/17/2026

1. NFLX
2. ISRG
3. SPY
4. AAPL
5. USB
6. NVDA
7. GCTK
8. CFG
9. STT
10. SPCX

Go back to Tezepelumab Granted Priority Review By U.S. FDA
Amgen Inc (NASDAQ: AMGN) Delayed: 366.29 -5.29 (1.42%)
Previous Close $371.58    52 Week High $176.85 
Open $373.97    52 Week Low $133.64 
Day High $378.54    P/E 55.16 
Day Low $361.72    EPS $6.64 
Volume 2,861,316